Synchronous resection of primary colorectal tumor, liver metastases safe in some patients
the ONA take:
A recent study examined and compared patient outcomes associated with synchronous and sequential colorectal and liver resections in patients with stage IV colorectal cancer.
Generally, a combination therapy involving chemotherapy and surgical resection is used to treat colorectal cancer, but debate remains as to whether metastatic tumors should be surgically removed at the same time as the primary tumors (synchronously), as opposed to a sequential approach.
Researchers from the Mayo Clinic, led by David Nagorney, M.D., used a multi-institutional database to review a pool of 43,408 patients who underwent colorectal and liver resections for stage IV colorectal cancer. Individuals in the pool were assigned risk categories based on the extent of resection, as well as colorectal resection location.
The investigators compared outcomes within each category, comparing those that underwent synchronous colorectal and liver resections vs those who had these operations performed sequentially. The study goal was to evaluate the risk of the component operations and determine which combination of colon and liver procedures was safest.
Study data indicate that poor patient outcomes are tied more closely to the risk of individual procedures as opposed to timing. major complications are linked to the extent of resection required (liver resection or colorectal surgery).
The study data also indicate that synchronous resection of primary colorectal tumors and metastatic liver tumors is safe when minor liver resections are required.
Study results were published in Journal of Gastrointestinal Surgery.
Patient outcomes associated with synchronous and sequential colorectal and liver resections in patients with stage IV colorectal cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|